NEWTON, Mass., Dec. 8, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team and Dr. Claire Harrison will participate in a virtual fireside chat as part of Baird's Biotech Discovery Series on Wednesday, December 10, 2025 at 12:00 p.m. ET. Dr. Harrison is Professor of Myeloproliferative Neoplasms, Clinical Director at Guy's and St. Thomas' NHS Foundation Trust and ...

A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor section of the Company's website, https://investors.karyopharm.com/events-presentations, and will be available for replay following the event. About Karyopharm Therapeutics Accessibility StatementSkip Navigation NEWTON, Mass., Dec. 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's ...

Core Viewpoint - Ascentage Pharma Group International is actively participating in investor conferences in December 2025, highlighting its ongoing commitment to engage with the investment community and showcase its advancements in biopharmaceuticals targeting unmet medical needs in cancer [1][7]. Company Overview - Ascentage Pharma is a global, commercial stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for cancer [2]. - The company has developed a robust pipeline of innovative drug products, including inhibitors targeting key apoptotic pathway proteins and next-generation kinase inhibitors [2]. Product Approvals and Trials - The first approved product, Olverembatinib, is a third-generation BCR-ABL1 inhibitor for treating chronic myeloid leukemia (CML) with specific mutations, currently undergoing a global Phase III trial [3]. - The second approved product, Lisaftoclax, is a Bcl-2 inhibitor for hematologic malignancies, with multiple global Phase III trials underway, including studies in chronic lymphocytic leukemia and acute myeloid leukemia [4]. Research and Development Partnerships - Ascentage Pharma has established a portfolio of global intellectual property rights and formed partnerships with leading biotechnology and pharmaceutical companies, including Takeda, AstraZeneca, Merck, and Pfizer, as well as collaborations with prominent research institutions [5].

Core Insights - Karyopharm Therapeutics has secured $100 million in financing to enhance financial flexibility and extend its cash runway into Q2 2026, supporting ongoing clinical trials and operations [1][5][10] - Preliminary total revenue for Q3 2025 is expected to be between $42 million and $44 million, with U.S. XPOVIO net product revenue projected at approximately $32 million [6][7] - The company is on track to report top-line data from the Phase 3 SENTRY trial in myelofibrosis by March 2026 [1][9] Financing Transactions - The financing includes a private placement of 1,487,917 shares of common stock and warrants to purchase 1,317,771 shares at an exercise price of $6.64, expected to generate approximately $8.75 million in gross proceeds [2][3] - The company will issue a total of 7,223,982 new shares and various warrants, with a reduction in the exercise price of existing warrants from $16.50 to $6.64 [3][5] - The financing aims to comply with Nasdaq rules and is structured to strengthen the balance sheet and equitize near-term debt maturities [1][3] Clinical Trials and Programs - The Phase 3 SENTRY trial is evaluating selinexor in combination with ruxolitinib for myelofibrosis, with co-primary endpoints focused on spleen volume reduction and symptom score improvement [13] - Enrollment is ongoing in the Phase 3 XPORT-EC-042 trial for endometrial cancer, with top-line data expected in mid-2026 [9][17] - Karyopharm's lead compound, selinexor, is positioned as a potential first combination therapy for myelofibrosis, aiming to redefine treatment standards [1][15] Financial Position - Prior to the financing, Karyopharm reported approximately $46 million in cash and equivalents as of September 30, 2025 [7][8] - The financing transactions are expected to provide significant financial flexibility, including $67.5 million in new capital and deferrals of interest and royalty payments [5][10]

Core Points - Karyopharm Therapeutics Inc. will report its second quarter 2025 financial results on August 11, 2025, at 8:00 a.m. ET [1] - A conference call and audio webcast will be hosted by the management team to discuss the financial results and company updates [1] Company Overview - Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on pioneering novel cancer therapies, particularly oral compounds that address nuclear export dysregulation [3] - The company's lead compound, XPOVIO® (selinexor), is an oral exportin 1 (XPO1) inhibitor approved in the U.S. for three oncology indications and has received regulatory approvals in various international markets, including Europe and China [3] - Karyopharm has a focused pipeline targeting high unmet need cancers, including multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL) [3]